Menarini Raunaq Pharma

Menarini Raunaq Pharma Limited, a joint venture company set up by the Raunaq group of India and Menarini group of Italy has introduced Pharmaceuticals specialties in the Indian market 6 years back. Raunaq group is amongst top industrial groups in India having substantial presence in diversified fields.

The group has been constantly evaluating various business opportunities to consolidate its industrial presence in the country and has also entered the Pharmaceutical business with financial and technical collaboration with Menarini group of Italy.

Menarini is the largest pharmaceutical group in Italy having affiliates/ joint ventures in several countries with the current global turnover exceeding US$ 2 billion. The product mix of Menarini covers several important therapeutic groups which has made the group as one of the fastest growing pharmaceutical group in the world. The products of Menarini are currently sold in over 100 countries of the world.

Menarini group has six research centers in Europe and the group spends over 13% of its turnover every year in research activities for development of new molecules and therapies. With 800 scientists working in various research centers, Menarini group is focusing its research activities in Gastrointestinal, Antibiotics, Cardiovascular and Oncology Therapeutic categories.

The joint venture company in India, Menarini Raunaq Pharma Limited has introduced pharmaceutical specialties and have successfully launched the products in Therapeutic groups of Gastrointestinal, Antibiotics and Cardiovascular segments. Menarini Raunaq Pharma Limited has now a strong marketing team of about 200 personnel comprising of Regional Sales Managers, Area Managers and Professional Services Officers in different parts of the country. The marketing team has been highly trained to handle the specialized products that are being promoted to the Medical profession.

Menarini Raunaq Pharma Limited is shortly going to introduce new research molecules of Menarini International in the Indian market and these products are currently in various stages of Clinical Trials / Approvals by the Drug Controller of India. The company plans to introduce new molecules which cover those therapeutic groups which are relevant to the tropical diseases prevalent in our country.

The desire of the company is to be truly research and customer oriented with a motto to work with Medical profession as an active member of their "Patient Care Team".